Post-earnings recap
Reported
Thu, Feb 27, 2025
EPS actual
$-0.88
EPS est.
$-0.76
EPS surprise
-15.49%
1-day move
-14.45%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Kymera Therapeutics is facing difficulties, particularly reflected in their EPS miss. The stock's sharp decline of 14.45% suggests investor disappointment and concern over the company's current trajectory. Without revenue figures or guidance, uncertainty remains high for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.88 | N/A | -15.49% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concerns about recent performance but remained focused on future objectives. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a commitment to long-term goals despite current setbacks.